HIMS vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HIMS demonstrates strong operational health with a Piotroski F-Score of 7/9, signaling robust financial trends and efficiency. However, the stock is severely overvalued from a deterministic standpoint, trading at $29.39 against a Graham Number of $5.23 and an Intrinsic Value of $3.57. While revenue growth is strong (28.4%) and gross margins are impressive (73.83%), the valuation premium is extreme. This, combined with bearish insider selling and a negative technical trend, offsets the company's fundamental operational strengths.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
HIMS vs LLY: Head-to-Head Comparison
This page compares Hims & Hers Health, Inc. (HIMS) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.